A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
Part of paid clinical trials in Alabaster, Alabama.
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- Study ID
- NCT04542057
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 40 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- Ensifentrine — DRUGDosage Formulation: Ensifentrine Nebulizer suspension Dosage 3mg Frequency: Twice Daily for 24 weeks
- Placebo — DRUGDosage Formulation: Ensifentrine Placebo Nebulizer solution Frequency: Twice Daily for 24 weeks
Study Details
The purpose of this study is to determine if ensifentrine is safe and effective for the treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
Key Dates
- First listed
- Sep 9, 2020
- Start date
- Sep 22, 2020
- Status verified
- Oct 2023
- Primary completion
- May 3, 2022
- Completion
- Jul 6, 2022
Study Design
- Enrollment
- 790 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm 1Ensifentrine Nebulized Suspension; 3 mg twice daily for 24 weeks
- Placebo Comparator: Arm 2Ensifentrine Placebo Nebulized Solution; twice daily for 24 weeks
Primary Outcome Measure
Least Square (LS) Mean Change From Baseline in Average Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12h) at Week 12 [ Time Frame: Baseline (40 minutes before first administration on Day 1) and Week 12 ]
Locations (77)
Find similar trials in Alabaster, AL
By condition
By specialty
Related Studies
- Boston Early-Onset Chronic Obstructive Pulmonary Disease (COPD) StudyRecruiting · Brigham and Women's Hospital · Boston, Massachusetts
- Hyper Polarized Xenon-129 MRI vs Xenon-133 ScintigraphyPHASE1/PHASE2 · Recruiting · University of Virginia · Charlottesville, Virginia
- Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through ExerciseRecruiting · Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota
- The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)PHASE2 · Recruiting · University of California, San Diego · La Jolla, California